New drug cocktail targets breast cancer in the brain

NCT ID NCT07263425

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jan 02, 2026 · Last updated May 23, 2026 · Updated 27 times

Summary

This study tests whether giving two drugs (thiotepa and trastuzumab) directly into the fluid around the brain and spinal cord can shrink tumors in the brain lining caused by HER2-positive breast cancer. About 26 people with this specific type of cancer spread will receive the treatment through a small device placed under the scalp (Ommaya reservoir). The goal is to see if the combination is safe and effective at controlling the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS OF HER2-POSITIVE BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jiangsu Provincial People's Hospital
RECRUITING

Nanjing, Jiangsu, 210000, China

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

LEPTOMENINGEAL METASTASIS OF HER2-POSITIVE BREAST CANCER